TITLE

What are the Current Advances Regarding HIV Vaccines and HIV Vaccine Trials?

AUTHOR(S)
Dhalla, Shayesta
PUB. DATE
May 2012
SOURCE
Journal of Bioanalysis & Biomedicine;2012, Vol. 4 Issue 3, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Editorial
ABSTRACT
The author discusses the current advances on HIV vaccines around the world. She offers her views on the unsuccessful STEP study, a clinical trial which tested the efficacy of an HIV vaccine. The STEP study was stopped in 2007, which revealed an increase in HIV infection for the first 18 months in uncircumcised men who had neutralizing antibodies to adenovirus-5 (Ad5) at baseline.
ACCESSION #
78392079

 

Related Articles

  • Merck HIV Vaccine Ineffective in Clinical Trial. Elliott, William T. // Primary Care Reports;Nov2007, Vol. 13 Issue 11, p2 

    The article reports that Merck HIV vaccine was ineffective in a large clinical trial. Merck announced that it already halted further test vaccinations. Although work continues on other HIV vaccines, with 30 worldwide in clinical trials at present, the failure of the Merck vaccine is seen is a...

  • A qualitative evaluation of volunteers' experiences in a phase I/II HIV vaccine trial in Tanzania.  // BMC Infectious Diseases;2011, Vol. 11 Issue 1, p283 

    The article discusses a study which evaluated the experiences of volunteers in an HIV vaccine trial in Dar es Salaam, Tanzania. The study found that during the phase I/II HIV vaccine trial, participants had the opportunities and the ability to cope with the doubts from the surrounding community....

  • Safety and Immunogenicity of a Replication-Defective Adenovirus Type 5 HIV Vaccine in Ad5-Seronegative Persons: A Randomized Clinical Trial (HVTN 054). Peiperl, Laurence; Morgan, Cecilia; Moodie, Zoe; Li, Hongli; Russell, Nina; Graham, Barney S.; Tomaras, Georgia D.; De Rosa, Stephen C.; McElrath, M. Juliana // PLoS Clinical Trials;Oct2010, Vol. 7 Issue 10, Special section p1 

    Background: Individuals without prior immunity to a vaccine vector may be more sensitive to reactions following injection, but may also show optimal immune responses to vaccine antigens. To assess safety and maximal tolerated dose of an adenoviral vaccine vector in volunteers without prior...

  • HIV vaccine may raise risk. Ledford, Heidi // Nature;11/15/2007, Vol. 450 Issue 7168, p325 

    The article reports on the failure of Human immunodeficiency virus (HIV) vaccine made by Merck to pass the clinical trials which could result to increase the susceptibility of some trial participants to the acquired immune deficiency syndrome (AIDS) virus. The findings have left scientists to...

  • Cold shower for AIDS vaccines.  // Nature Medicine;Dec2007, Vol. 13 Issue 12, p1389 

    The author reflects on the goal of developing AIDS vaccines that remains out of reach. He highlights the fact that HIV mutates in response to drugs, it mutates in response to immune pressure, it co-opts multiple cellular pathways to evade detection or destruction, it hides in reservoirs, and,...

  • Rational design of HIV vaccine and microbicides: report of the EUROPRISE annual conference. Wahren, Britta; Biswas, Priscilla; Borggren, Marie; Coleman, Adam; Da Costa, Kelly; De Haes, Winni; Dieltjens, Tessa; Dispinseri, Stefania; Grupping, Katrijn; Hallengärd, David; Hornig, Julia; Klein, Katja; Mainetti, Lara; Palma, Paolo; Reudelsterz, Marc; Seifried, Janna; Selhorst, Philippe; Sköld, Annette; van Gils, Marit J.; Weber, Caroline // Journal of Translational Medicine;2010, Vol. 8, p72 

    EUROPRISE is a Network of Excellence sponsored from 2007 to 2011 by the European Commission within the 6th Framework Program. The Network encompasses a wide portfolio of activities ranging from an integrated research program in the field of HIV vaccines and microbicides to training,...

  • The 2010 scientific strategic plan of the Global HIV Vaccine Enterprise. Berkley, Seth; Bertram, Kenneth; Delfraissy, Jean-François; Draghia-Akli, Ruxandra; Fauci, Anthony; Hallenbeck, Cynthia; Kagame, Madame Jeannette; Kim, Peter; Mafubelu, Daisy; Makgoba, Malegapuru W; Piot, Peter; Walport, Mark; Warren, Mitchell; Yamada, Tadataka; Esparza, José; Hankins, Catherine; Johnston, Margaret I.; Lévy, Yves; Romaris, Manuel; Ahmed, Rafi // Nature Medicine;Sep2010, Vol. 16 Issue 9, p981 

    The article focuses on the scientific strategic plan of Global HIV Vaccine Enterprise in 2010. It states that the Global HIV Vaccine Enterprise is a coalition of independent organizations which were committed to develop an HIV vaccine by making scientific strategic plan, increasing resources,...

  • Pre-Existing Adenovirus Immunity Modifies a Complex Mixed Th1 and Th2 Cytokine Response to an Ad5/HIV-1 Vaccine Candidate in Humans. Pine, Samuel O.; Kublin, James G.; Hammer, Scott M.; Borgerding, Joleen; Yunda Huang; Casimiro, Danilo R.; McElrath, M. Juliana // PLoS ONE;2011, Vol. 6 Issue 4, p1 

    The results of the recent Step Study highlight a need to clarify the effects of pre-existing natural immunity to a vaccine vector on vaccine-induced T-cell responses. To investigate this interaction, we examined the relationship between preexisting Ad5 immunity and T-cell cytokine response...

  • HIV vaccine trial expands. Bajko, Matthew S. // Bay Area Reporter;10/6/2005, Vol. 35 Issue 40, p12 

    Reports that HIV vaccine researchers are expressing cautious optimism on the outcome of a new trial as they expand the number of people in the four-year long study in San Francisco, California. Use of the vaccine with a weakened adenovirus 5 (ad5) which can neither reproduce itself nor give a...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics